Key facts
- It has raised $1.4M; the latest was Early Stage VC in Feb 2026.
- Notable investors include Changxing Fund, The Chinese Academy of Sciences Venture Capital Management.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Zhongke Health-EV
- ·The full record, as it builds
Funding rounds
No funding rounds for Zhongke Health-EV are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Zhongke Health-EV
Developer of diagnostic products and services designed for exosomes. The company's products mainly focus on precision medicine for cancer and neurodegenerative diseases, which is committed to providing systematic products and services for early diagnosis and accurate diagnosis of major diseases, providing customers with accurate and innovative products.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2022
- Ownership
- Privately Held (backing)
Zhongke Health-EV doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Zhongke Health-EV shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Zhongke Health-EV in its N-PORT filings yet. We sweep new filings monthly.